SGLT1 is a novel cardiac glucose transporter that is perturbed in disease states. - Wikidata - awgldk - TriplyDB

SGLT1 is a novel cardiac glucose transporter that is perturbed in disease states.

SGLT1 is a novel cardiac glucose transporter that is perturbed in disease states.

http://www.wikidata.org/entity/Q37341063

about

SGLT1, a novel cardiac glucose transporter, mediates increased glucose uptake in PRKAG2 cardiomyopathy Development of a novel non-radioactive cell-based method for the screening of SGLT1 and SGLT2 inhibitors using 1-NBDG.Transgenic knockdown of cardiac sodium/glucose cotransporter 1 (SGLT1) attenuates PRKAG2 cardiomyopathy, whereas transgenic overexpression of cardiac SGLT1 causes pathologic hypertrophy and dysfunction in mice.Expression of SGLT1 in Human Hearts and Impairment of Cardiac Glucose Uptake by Phlorizin during Ischemia-Reperfusion Injury in Mice.Intracellular Na+ Concentration ([Na+]i) Is Elevated in Diabetic Hearts Due to Enhanced Na+-Glucose Cotransport.Gene-Targeted Mice with the Human Troponin T R141W Mutation Develop Dilated Cardiomyopathy with Calcium Desensitization Cardioprotective effect of ritonavir, an antiviral drug, in isoproterenol induced myocardial necrosis: a new therapeutic implication Rationale and design of a randomized trial to test the safety and non-inferiority of canagliflozin in patients with diabetes with chronic heart failure: the CANDLE trial.Localisation of AMPK γ subunits in cardiac and skeletal muscles JAK-STAT signaling and myocardial glucose metabolism.Sodium glucose cotransporter 1 ligand BLF501 as a novel tool for management of gastrointestinal mucositis.Sodium-myoinositol cotransporter-1, SMIT1, mediates the production of reactive oxygen species induced by hyperglycemia in the heart.Real-time imaging of sodium glucose transporter (SGLT1) trafficking and activity in single cells Energetics and metabolism in the failing heart: important but poorly understood.Inhibition of the sodium glucose co-transporter-2: its beneficial action and potential combination therapy for type 2 diabetes mellitus.Mechanisms of subcellular remodeling in heart failure due to diabetes.SGLT inhibitors: a novel target for diabetes.Sodium glucose cotransporter SGLT1 as a therapeutic target in diabetes mellitus.Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus.Novel Sulfur Metabolites of Garlic Attenuate Cardiac Hypertrophy and Remodeling through Induction of Na+/K+-ATPase Expression.Synthesis and SAR of Benzisothiazole- and Indolizine-β-d-glucopyranoside Inhibitors of SGLT2.Glucose transporters: physiological and pathological roles.Diallyl disulfide ameliorates isoproterenol induced cardiac hypertrophy activating mitochondrial biogenesis via eNOS-Nrf2-Tfam pathway in rats Metabolic Origins of Heart Failure.The effect and action mechanism of resveratrol on the vascular endothelial cell by high glucose treatment.Structural insights into genetic variants of Na(+)/glucose cotransporter SGLT1 causing glucose-galactose malabsorption: vSGLT as a model structure.Expression profiling and immunolocalization of Na+-D-glucose-cotransporter 1 in mice employing knockout mice as specificity control indicate novel locations and differences between mice and rats.A novel and selective sodium-glucose cotransporter-2 inhibitor, tofogliflozin, improves glycaemic control and lowers body weight in patients with type 2 diabetes mellitus.Direct cardiovascular impact of SGLT2 inhibitors: mechanisms and effects.Cardiac effects of SGLT2 inhibitors: the sodium hypothesis.Interaction of the Sodium/Glucose Cotransporter (SGLT) 2 inhibitor Canagliflozin with SGLT1 and SGLT2.Nitric oxide synthase inhibition abrogates hydrogen sulfide-induced cardioprotection in mice.Dual inhibition of sodium–glucose linked cotransporters 1 and 2 exacerbates cardiac dysfunction following experimental myocardial infarction.NADPH oxidase activation by hyperglycaemia in cardiomyocytes is independent of glucose metabolism but requires SGLT1 Myocyte [Na] Dysregulation in Heart Failure and Diabetic Cardiomyopathy

P2860

Q34101200-C3A979FD-5B42-4577-9AAB-5AE17AB87EF7 Q34343670-464B968A-052E-49DB-BFB1-F14514EFC0AD Q35026241-26BEFCBF-0913-4BD9-AD88-8B32B80F0127 Q35677381-B2CA7B10-EE5E-4507-8F2B-6C576D19C214 Q36141842-33F136BD-2B86-4FD0-854B-C772E543E4F8 Q36217967-DC3F6E17-5C19-4B6A-BD90-5689179D5451 Q36758710-C2599CAE-9570-4A4A-B3EB-E8488029A41F Q36765350-B9E41438-AA25-4158-BF03-ACDAB977B97D Q37368921-57C679B5-7FAF-4BFA-AAB9-C34AD5BE99A9 Q37421817-58C4EC94-25B5-4C25-B08E-DCDE9C45D9BF Q37607488-05DFE3CB-15C7-43DF-9EE2-946FC158E146 Q37609275-7DA3EC94-027E-4EBA-8AE0-18FBA8F17AF8 Q37642406-0783A056-5C95-4F99-A94C-F66886C3D28A Q37746834-35C5BC60-54E2-4B88-956E-0F3CF2610F28 Q38075117-687C0352-AC9E-40A7-9EC5-B7D6A2F6B532 Q38084193-CBF77C38-6D8F-4BDA-91DB-24939E34D218 Q38162956-63953A0B-EAFF-4A08-917A-C8C4121D59A1 Q38783130-FB732897-D63E-449B-97B6-90C1E6A1E603 Q38827756-CD2963C6-828C-44A5-B197-931F32B1F1FF Q38963183-2A21C540-397D-4B2C-8FA0-EDA3F4DD618F Q39159537-22DC3D23-43DB-4B93-A40E-81245201EDB8 Q39310744-CECA2A83-58EC-412F-95BF-3E3A85DD5E6C Q41683440-A78E133A-9195-442C-9FDA-DA620502C697 Q41700538-48FBE53C-F95F-4BA8-A0CE-1009866155D6 Q42544567-04AC3C67-7BB5-4B70-933D-EF98177D99C7 Q44190263-04EAECCC-814B-48A3-AA82-C3FEC15BC506 Q47164947-D122F515-E980-4E3C-AB83-8C55E7C9DA2C Q47374718-008D266C-1647-4730-BA84-DA4EA623DABC Q47739163-8E6DA69E-9084-44D4-880A-8C0AF1C1A309 Q50089120-64C17E24-E756-45D1-B3F7-8A23928A7104 Q51737719-5F057EA2-2352-4612-908A-F42ABCF2719B Q53222723-54EF3E6D-CAFE-42CE-8CC4-41F666140571 Q55457178-314E8BC2-61C1-4FF0-B33F-5DD7A12DAAB1 Q57779362-AA765F52-E474-43B9-93BF-70711B65859D Q58746196-9BA8C570-72C4-4EC2-9695-2FFDB6992591

P2860

SGLT1 is a novel cardiac glucose transporter that is perturbed in disease states.

http://www.wikidata.org/entity/Q37341063

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 09 June 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

SGLT1 is a novel cardiac glucose transporter that is perturbed in disease states.

@en

SGLT1 is a novel cardiac glucose transporter that is perturbed in disease states.

@nl

type

label

SGLT1 is a novel cardiac glucose transporter that is perturbed in disease states.

@en

SGLT1 is a novel cardiac glucose transporter that is perturbed in disease states.

@nl

prefLabel

SGLT1 is a novel cardiac glucose transporter that is perturbed in disease states.

@en

SGLT1 is a novel cardiac glucose transporter that is perturbed in disease states.

@nl

P1433

Q37341063-51F98A39-A889-4972-85FD-1015BA090309

P1476

Q37341063-C7E722A8-1A90-4D6A-A010-D171CA6F2EC0

P2093

Q37341063-04155679-73B5-4666-BA95-37E89336ACCC

Q37341063-60F2D0B9-58D3-4733-A337-EFADF8A16445

Q37341063-755C67E4-2C57-4A4C-9868-C7726E569115

Q37341063-DF7398D1-B98C-4D55-B20B-8AC6F8A95AA2

P2860

Q37341063-066E67CB-7928-47FE-A30E-8D61ACBBE93B

Q37341063-0C7A827E-24EB-4909-972B-F444D9DBA9E6

Q37341063-1C6C6367-FFFB-43F5-8100-D3A2F616489F

Q37341063-2D8C7127-D312-4E75-B6C0-66F6D31D9643

Q37341063-376C3DF0-064D-43D4-86F7-59713908BF20

Q37341063-5EF5C0EC-1582-40B2-AE48-990CFC2D74A4

Q37341063-6244E0A9-88BF-4194-BFB9-A5857E3F52E5

Q37341063-687DBC9D-A548-4F6D-A3C2-817CABD485BC

Q37341063-74D20ECD-133E-47CB-8A70-42CFCED40C95

Q37341063-7C1D8609-D56D-4BAD-8D7B-71DF841EF444

P304

Q37341063-7098B1E0-B230-48D6-9E24-7FAE44294292

P31

Q37341063-7E7602F4-9E37-4012-925A-691BD3900DD7

P356

Q37341063-189B9374-C563-46F0-98C6-F0C0B6906AF1

P433

Q37341063-CE9CF99C-497F-41D5-982A-8CC308F4D012

P478

Q37341063-63F247F9-8C6E-4AFF-9030-4EC75B434DE3

P577

Q37341063-1EDCB499-2DD9-403F-A5BD-FDC3931F900C

P5875

Q37341063-762E61F4-53E1-45F5-9019-EF4506F99806

P698

Q37341063-741F9FA5-D981-4A9E-8804-4E9D42277E46

P921

Q37341063-35BCD560-A5CD-4677-A7DA-D0E86DF7B4B9

Q37341063-8cc2738e-2e3f-4e25-9fff-c8b803ad1f66

P932

Q37341063-2BE0E3D0-0075-44D6-BE9F-774BF876085F

P356

P1433

Cardiovascular Research

P1476

SGLT1 is a novel cardiac glucose transporter that is perturbed in disease states.

@en

P2093

Ferhaan Ahmad

http://www.w3.org/2001/XMLSchema#string

Kenneth R McGaffin

http://www.w3.org/2001/XMLSchema#string

Núria M Pastor-Soler

http://www.w3.org/2001/XMLSchema#string

Sanjay K Banerjee

http://www.w3.org/2001/XMLSchema#string

P2860

Cardiac hypertrophy with preserved contractile function after selective deletion of GLUT4 from the heart

Glucose/galactose malabsorption caused by a defect in the Na+/glucose cotransporter

Membrane topology of the human Na+/glucose cotransporter SGLT1

Active sugar transport in health and disease

The role of cardiac troponin T quantity and function in cardiac development and dilated cardiomyopathy.

Aquaporin 9 expression along the male reproductive tract.

Human cardiomyocytes express high level of Na+/glucose cotransporter 1 (SGLT1).

Alkaline pH- and cAMP-induced V-ATPase membrane accumulation is mediated by protein kinase A in epididymal clear cells.

Myocardial substrate metabolism in the normal and failing heart.

Cloning of a membrane-associated protein which modifies activity and properties of the Na(+)-D-glucose cotransporter.

P304

111-118

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/CVR/CVP190

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

84

http://www.w3.org/2001/XMLSchema#string

P577

2009-06-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26278605

http://www.w3.org/2001/XMLSchema#string

P698

19509029

http://www.w3.org/2001/XMLSchema#string

P921

P932

2741348

http://www.w3.org/2001/XMLSchema#string